Abstract：【Objective】 To explore the clinical efficacy of sacubitril/valsartan in the treatment of patients with heart failure with reduced ejection fraction(HFrEF) and its impact on patients' cardiac function and quality of life.【Methods】 The clinical data of 90 HFrEF patients admitted to Xuchang Central Hospital from May 2023 to May 2024 were selected. According to different treatment regimens, the patients were divided into the control group(routine anti-heart failure treatment) and the observation group(valsartan was discontinued on the basis of the control group, and sacubitril/valsartan sodium tablets were added), with 45 cases in each group. The clinical efficacy, cardiac function indicators [left ventricular ejection fraction(LVEF), left atrial diameter(LAD), left ventricular end-diastolic diameter(LVEDD)], ventricular remodeling indicators [interventricular septal thickness(IVST), left ventricular posterior wall thickness(LVPWT), left ventricular mass index(LVMI)], laboratory indicators [high-sensitivity C-reactive protein(hs-CRP), B-type natriuretic peptide(BNP)], quality of life [Minnesota Living with Heart Failure Questionnaire(MLHFQ) score] and exercise tolerance [6-minute walk distance(6MWD)] were compared between the two groups.【Results】 The clinical effective rate of the observation group was higher than that of the control group, with a statistically significant difference(P<0.05). After treatment, the LVEF of both groups was higher than that before treatment, while LAD and LVEDD were lower than those before treatment; the LVEF of the observation group was higher than that of the control group, and LAD and LVEDD were lower than those of the control group, with statistically significant differences(P<0.05). After treatment, the IVST, LVPWT and LVMI of both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences(P<0.05). After treatment, the serum levels of hs-CRP and BNP in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences(P<0.05). After treatment, the MLHFQ scores of both groups were lower than those before treatment, and 6MWD was longer than that before treatment; the MLHFQ score of the observation group was lower than that of the control group, and 6MWD was longer than that of the control group, with statistically significant differences(P<0.05).【Conclusion】 Sacubitril/valsartan sodium tablets have good clinical efficacy in the treatment of HFrEF patients. They can effectively reduce the cardiac load of patients, inhibit pathological ventricular remodeling, and improve patients' quality of life and exercise tolerance.
杨晓静, 张青德. 沙库巴曲缬沙坦治疗HFrEF患者的临床疗效及对患者心功能、生活质量的影响[J]. 医学临床研究, 2025, 42(9): 1545-1548.
YANG Xiaojing, ZHANG Qingde. The Clinical Efficacy of Sacubitril/Valsartan in the Treatment of Patients with HFrEF and its Impact on Cardiac Function and Quality of Life. JOURNAL OF CLINICAL RESEARCH, 2025, 42(9): 1545-1548.
2025, Vol. 42 
